Sirolimus

BARCELONA, Spain - New Approach to Coronary Stenting Shows Superior Results in Key Six-Month Safety and Efficacy Endpoints At six months, the NEVO(TM) Sirolimus-eluting Coronary Stent, incorporating RES Technology(TM), was superior to the Taxus(R) Liberte(R) Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results released today.